I. Major adverse reactions of IFNα. For flu-like syndrome, bone marrow suppression, mental abnormalities, thyroid disease, loss of appetite, weight loss, diarrhea, rash, hair loss and sterile inflammation at the injection site, etc. 1. Flu-like syndrome: manifested as fever, chills, headache, muscle pain and weakness, etc. IFNα can be injected at bedtime or non-steroidal anti-inflammatory and analgesic drugs can be taken at the same time as IFNα injection to reduce flu-like symptoms. With the progress of treatment, such symptoms will gradually reduce or disappear. 2. Myelosuppression: Transient myelosuppression is mainly manifested as a decrease in peripheral blood leukocytes and platelets. If the absolute number of neutrophils ≤ 0.75×109/L and platelets <50×109/L, the dose of IFNα should be reduced; recheck after 1 to 2 weeks, and if it recovers, gradually increase to the original amount. If the absolute number of granulocytes ≤ 0.50×109/L and platelets < 30×109/L, the drug should be discontinued. For those with significantly lower neutrophils, granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) can be used for treatment. 3.Psychiatric abnormalities: can be manifested as depression, paranoia, severe anxiety and psychosis. Among them, depression is a common adverse reaction during IFNα treatment, and the symptoms can range from irritability to severe depression. Therefore, the patient's mental status should be assessed before using IFNα and closely observed during treatment. Antidepressants may alleviate such adverse reactions. IFNα should be discontinued promptly for those with severe symptoms. 4. IFNα can induce the production of autoantibodies: including anti-thyroid antibodies, anti-nuclear antibodies and anti-insulin antibodies. In most cases, there is no obvious clinical manifestation. Some patients may develop thyroid disease (hypo- or hyperthyroidism), diabetes mellitus, thrombocytopenia, hemolytic anemia, psoriasis, leukoplakia, rheumatoid arthritis and systemic lupus erythematosus-like syndrome, etc. The drug should be discontinued in serious cases. 5, other rare adverse reactions: including renal damage (interstitial nephritis, nephrotic syndrome and acute renal failure, etc.), cardiovascular complications (arrhythmia, ischemic heart disease and cardiomyopathy, etc.), retinopathy, hearing loss and interstitial pneumonia, etc. When these reactions occur, treatment should be discontinued. Second, the main adverse reactions of ribavirin. The main adverse reactions of ribavirin are hemolytic and teratogenic effects. 1, timely detection of hemolytic anemia: regular hematological tests must be done, including hemoglobin, red blood cell count and reticulocyte count. In renal insufficiency can cause severe hemolysis and ribavirin should be disabled. The dose should be reduced when Hb drops to ≤100g/L; the drug should be discontinued when Hb ≤80g/L. 2. Teratogenicity: Both male and female patients should use contraception during treatment and for 6 months after discontinuation of the drug. 3, other adverse reactions: Ribavirin can also cause nausea, dry skin, itching, cough and hyperuricemia.